ArticleBioresources and bioprocessing2026
Engineering of Corynebacterium glutamicum for the enhanced production of optically pure (meso)-2,3-butanediol.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modular synthetic cross-kingdom promoters enable coordinated expression in Escherichia coli and Saccharomyces cerevisiae.Nucleic acids research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
2,3-Butanediol (2,3-BDO) is a versatile platform chemical with diverse applications in cosmetics, pharmaceuticals, agricultural and food manufacturing. Among its stereoisomers, optically pure (meso)-2,3-BDO is particularly valuable; however, achieving high titers with stereoselectivity remains challenging in conventional hosts due to byproduct formation, low tolerance, and plasmid instability. In this study, we established Corynebacterium glutamicum as an efficient and robust chassis for the industrial-level production of optically pure (meso)-2,3-BDO. A structure-guided engineering approach was applied to 2,3-butanediol dehydrogenase (KpBDH), where α6-helix truncation enhanced catalytic efficiency and enabled near-complete conversion of acetoin to the target isomer. To further improve productivity, competing byproduct pathways were deleted, and cofactor homeostasis was reinforced by integrating UdhA for NADH regeneration and DrPPK for ATP regeneration. Finally, all biosynthetic modules were stably integrated into the chromosome, generating the plasmid-free strain ES11. In 5L fed-batch fermentation, ES11 produced 100.4 ± 0.4 g/L (meso)-2,3-BDO with > 99% optical purity, a yield of 0.33 ± 0.04 g/g glucose, and productivity of 0.82 ± 0.06 g/L/h. This work represents the first demonstration of > 100 g/L optically pure (meso)-2,3-BDO using C. glutamicum and establishes an integrated strategy of enzyme engineering, pathway optimization, and process design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.